Parathyroid hormone and growth in children with chronic renal failure  by Waller, Simon C. et al.
Kidney International, Vol. 67 (2005), pp. 2338–2345
Parathyroid hormone and growth in children with chronic
renal failure
SIMON C. WALLER, DEBORAH RIDOUT, TOM CANTOR, and LESLEY REES
Nephro-Urology Unit, Insitute of Child Health and Great Ormond Street Hospital for Children NHS Trust, London, United
Kingdom; Paediatric Epidemiology and Biostatistics Unit, Institute of Child Health and Great Ormond Street Hospital for Children
NHS Trust, London, United Kingdom; and Scantibodies Inc., Santee, California
Parathyroid hormone and growth in children with chronic renal
failure.
Background. In pediatric chronic renal failure (CRF) opti-
mal parathyroid hormone (PTH) concentrations that minimize
renal osteodystrophy and maximize growth are unknown. The
search for optimum concentrations has been complicated as cur-
rently used “intact” PTH (iPTH) assays cross-react with long
carboxyl-terminal PTH fragments (C-PTH), which antagonize
the biologic actions of 1-84 PTH. The purpose of this study was
to investigate the relationship between PTH, the 1-84 PTH:C-
PTH ratio and growth rate in children with CRF.
Methods. A total of 162 patients, median (range) age 9.9
years (0.3 to 17.1 years), were recruited: 136 with a glomerular
filtration rate (GFR) <60 mL/min/1.73 m2 [96 managed con-
servatively (CRF group) and 40 transplanted patients], and 26
dialysis patients. Over a median (range) period of 1.1 years
(0.5 to 1.7 years), children attended five (three to 15) clinics at
which iPTH, cyclase-activating PTH (CAP-PTH), and height
were measured.
Results. Mean PTH concentrations were within the normal
range for both assays for the CRF group and up to twice the
upper limit of normal for the dialysis group; CAP-PTH 24.8
pg/mL and 59.9 pg/mL (normal range 5 to 39 pg/mL), iPTH
37.1 pg/mL, and 102.6 pg/mL, respectively (normal range 14
to 66 pg/mL). The patients grew normally (change in height
standard deviation score per year (HtSDS) = −0.01). There
was no relationship between PTH concentrations and HtSDS
in any patient group. The 1-84 PTH:C-PTH ratio was lower in
dialyzed patients (P = 0.003), with worsening renal function
(P = 0.047) and with PTH concentrations outside the normal
range (P = 0.01). There was a weak correlation between the
1-84 PTH:C-PTH ratio and the HtSDS (r = 0.2, P = 0.01).
Conclusion. Normal range PTH concentrations are appro-
priate, allowing normal growth in children with CRF managed
conservatively. C-PTH may be of clinical significance.
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Disordered parathyroid hormone (PTH) secretion is
frequently encountered in chronic renal failure (CRF),
occurs early in the course of the disease and is pivotal
to the etiology of renal osteodystrophy [1, 2]. Optimum
management of hyperparathyroidism in children, who
have a lifetime of inadequate renal function ahead of
them, is particularly important because of the potential
to affect growth [3, 4] and because hyperparathyroidism
is an independent risk factor for cardiovascular disease
[5, 6].
In adults, recommendations are for raised PTH concen-
trations [7] as elevated concentrations have been found to
be required to maintain normal bone turnover in dialyzed
patients [8]. There is little evidence on which to base rec-
ommendations for optimum PTH concentrations in chil-
dren [9]. Pediatric histologic studies in dialyzed children
[10–13] concur with adult data regarding the relationship
between PTH concentrations, bone turnover and renal
osteodystrophy, but did not investigate or are inconsis-
tent with regard to effects upon growth. In children with
CRF prior to dialysis, data investigating the relationship
between PTH concentrations and growth are also incon-
sistent. PTH concentrations have been shown to be pos-
itively correlated with growth [14]. However, we have
demonstrated catch-up growth with PTH concentrations
at the upper limit of the normal range in children with
conservatively managed CRF [15].
Explanations of the necessity for supraphysiologic
PTH concentrations have been based upon the concept
of “skeletal resistance to PTH,” the mechanism for which
is unclear [16]. One cause may be that current “intact”
immunoradiometric (IRMA) PTH assays exhibit cross-
reactivity between 1-84 PTH and long carboxyl-terminal
PTH (C-PTH) fragments (likely to be 7-84 [17]), resulting
in an overestimation of the actual 1-84 PTH concentra-
tions [17–19]. Furthermore, it has been shown that 7-84
PTH has an inhibitory effect upon the biologic actions
of 1-84 PTH [20], mediated at a separate C-terminal re-
ceptor [21–23]. It is, therefore, possible that C-PTH is
implicated in PTH “resistance,” which is of particular
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importance as C-PTH concentrations increase with wors-
ening CRF [24, 25].
With the introduction of commercial assays [cyclase-
activating PTH (CAP-PTH)] (Scantibodies, Inc., San
Clemente, CA, USA, and BioIntact PTH, Nichols Insti-
tute) that specifically measure only 1-84 PTH [26, 27],
evidence for the clinical effects of C-PTH is emerging; in
particular the use of the 1-84 PTH:C-PTH ratio as a surro-
gate marker of bone turnover has been studied in patients
on dialysis. However, data relating a low ratio (i.e., a pre-
ponderance of 7-84 PTH) with low bone turnover are not
consistently reported [28–31]. Further investigation of
this ratio is needed [32].
If C-PTH has biologic activity in adults it is also likely to
antagonize the actions of 1-84 PTH in children as well. We
have previously demonstrated in children with CRF that
the relative proportion of C-PTH to 1-84 PTH increases
with worsening CRF and also with PTH concentrations
outside the normal range [25]. To date the effects, if any,
of C-PTH upon growth rate are undetermined. The aim
of this study was to investigate the relationship between
PTH, the 1-84 PTH:C-PTH ratio and longitudinal growth
in children with varying severity of CRF in order to pro-
vide evidence for optimal PTH concentrations.
METHODS
Patients
Between July 2001 and March 2003, patients with a
glomerular filtration rate (GFR) <60 mL/min/1.73 m2 or
on dialysis were recruited from CRF, dialysis, and trans-
plant clinics at Great Ormond Street Hospital. All pa-
tients not treated with growth hormone were approached.
Routine samples were collected for sodium, potassium,
bicarbonate, urea, creatinine, calcium, ionized calcium,
magnesium, phosphate, alkaline phosphatase, and albu-
min. Additional samples were collected for CAP-PTH
and intact PTH (iPTH) IRMA assays. Height, weight, and
pubertal stage were assessed by trained personnel using
standard techniques [33] (i.e., Harpenden stadiometer)
and information on medical therapy was collected.
Management of hyperparathyroidism begins in our
unit with the measurement of the iPTH concentration
when the GFR falls to 70 mL/min/1.73 m2. The aim has
been to try to prevent hyperparathyroidism; unlike many
pediatric units, maintaining PTH within the normal range
throughout the course of CRF in order to prevent es-
cape of the parathyroid gland from normal control mech-
anisms. We are able to attempt this as many patients
are referred antenatally or early in the course of their
disease and because we actively screen children with
bilateral renal defects by measurement of GFR by
ethylenediaminetetraacetic acid (EDTA) clearance.
Treatment begins with dietary phosphate restriction fol-
lowed by the introduction of calcium carbonate, aiming
Table 1. Plasma concentrations
iPTH represents 1-84 PTH and C-PTH
CAP-PTH represents 1-84 PTH
C-PTH = iPTH − CAP-PTH
to maintain the serum phosphate below the 50th cen-
tile for age as far as possible with minimal effect on
plasma calcium by giving with feeds. If necessary, alfacal-
cidol is prescribed at the smallest dose to increase serum
calcium to a level sufficient to suppress PTH to within
the normal range. The study was approved by the local
Research and Ethics Committee. Written consent was ob-
tained from parents and, where appropriate, participating
adolescents.
Assays
All PTH samples (EDTA plasma) were sent to the
laboratory immediately after blood was drawn, cen-
trifuged, and frozen at −70◦C for no longer than 4 months
before being sent to Scantibodies Clinical Laboratory,
Inc. for analysis. Both laboratories were blinded to all
clinical data. Plasma 1-84 PTH was determined by the
CAP-IRMA using an I-125 radiolabeled detection anti-
body with a specificity that is dependent on the presence
of the first amino acid from the N-terminal site (Whole
PTHTM) (Scantibodies Laboratory, Inc.). The reference
range of the assay in normal individuals is 5 to 39 pg/mL
with an assay sensitivity of 1.0 pg/mL and a linear mea-
surement range up to 2100 pg/mL for undiluted patient
samples. The intra- and interassay variances are less than
5% and 8%, respectively [26]. The plasma total iPTH
value was determined by an IRMA (Scantibodies Lab-
oratory, Inc.), which measured both 1-84 PTH and 7-84
PTH in an equal molar manner [34]. The total iPTH as-
say showed a detection sensitivity of 1.2 pg/mL and its
intra- and interassay variances are of less than 5% and
7%, respectively. Plasma concentrations of C-PTH were
determined by subtracting the CAP-PTH value from the
result of the iPTH. The 1-84 PTH: C-PTH ratio was then
calculated [28] (see Table 1).
Routine biochemistry (urea, creatinine, calcium, phos-
phate, alkaline phosphatase, and albumin) was measured
on a Vitros 750 analyzer (Johnson & Johnson, High
Wycombe, UK). Ionized calcium was determined using
a Ciba-Corning 634 calcium/pH electrode analyzer and
Bayer diagnostic reagents (Bayer Diagnostic Division,
Newbury, UK).
Statistics
Data were analyzed using SPSS version 10 (SPSS,
Chicago, IL, USA). Measurements that were not nor-
mally distributed were log (10) transformed, in order to
comply with the assumptions of the statistical methods
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Table 2. Demographic data and mean serum biochemical concentrations by patient group
Chronic renal Hemodialysis Peritoneal
All patients failure patients group dialysis group Transplant group
(N = 162) (N = 96) (N = 7) (N = 19) (N = 40) P value
Gender male:female% 69:31 70:30 43:57 68:32 70:30 = 0.52, v 2
Age median years old (range) 9.9 (0.3–17.1) 6.5 (0.3–16.9) 13.7 (2.8–16.1) 13.2 (5.6–16.9) 13.8 (3.8–17.1) <0.001, Kruskal-Wallis
Urea mmol/L (range) 11.7 (3.7–33.6) 11.1 (3.7–33.6) 21.8 (15.1–27.3) 15.1 (7.9–25.6) 10.5 (4.8–22.3) <0.001 ANOVA
Creatinine lmol/L (range) 184 (35–1186) 145 (35–679) 870 (507–1186) 712 (401–1027) 132 (61–521) <0.001 ANOVA
Median glomerular filtration rate 28 (7–60) 38 (13–60) =0.003 Mann-Whitney
mL/min/1.73 m2 (range)
ANOVA is analysis of variance. 95% CI for mean or range (as indicated) in parentheses.
used; these included serum urea and creatinine concen-
trations and PTH concentrations as measured by both
assays and also the 1-84 PTH:C-PTH ratio. Mean values
were therefore expressed as geometric means. Mean pa-
tient values were calculated for all biochemical markers
recorded over the duration of the study period and these
data were used to provide an overall summary of the
data. Analysis of variance (ANOVA) was used to assess
differences between several groups. Although details of
each patient group were given in demographic and bio-
chemical tables, the peritoneal and hemodialysis patients,
due to small numbers, were grouped together for some
analyses.
For skewed distributions, such as GFRs, the Mann-
Whitney test was used for comparison between two pa-
tient groups. Kruskal-Wallis test was used to compare
skewed data, such as age, between more than two patient
groups.
Phosphate concentrations are particularly age depen-
dent [35], thus an age-corrected phosphate concentration
was calculated by expressing the phosphate concentra-
tion as a proportion of the age dependent upper limit of
normal.
When investigating growth, standard deviation scores
(SDS) were calculated for height and weight using the
British 1990 growth reference; this summarizes the an-
thropometric measures from infancy to adulthood [36].
Changes to these data over the study period were stan-
dardized to rate of change of the SDS per year. One sam-
ple t tests were used to compare SDS values and changes
in SDS values with the general population. Pearson cor-
relation coefficients and regression analysis were used to
investigate the relationships between biochemical mark-
ers, SDS for anthropometric measures and other contin-
uous factors.
RESULTS
In total 162 [111 (69%) male] patients were recruited.
There were 96 children with a GFR <60 mL/min/1.73
m2, managed conservatively (CRF group), 40 renal trans-
plant patients with a GFR <60 mL/min/1.73 m2 (trans-
plant group), and 19 patients maintained on peritoneal
dialysis and seven on hemodialysis (dialysis group). Their
underlying diagnoses reflected those of any pediatric
CRF program. Data (anthropometric and serum sam-
ples) were collected for a median (range) of 1.1 years
(0.5 to 1.7 years), at five (three to 15) clinic visits. The
median age at inclusion was 9.9 years. However, the CRF
group was significantly younger, at 6.5 years (Table 2),
compared with other groups, 13.5 years (P < 0.01).
Over three fourths (78%) of patients had a formal 51
chromium EDTA (51Cr-EDTA) GFR investigation ei-
ther within the 18 months prior to commencement or
during the course of the research. The Schwartz formula
[37] was used to estimate the GFR of the remaining 22%
of patients: 26 from the CRF group and four from the
transplant group. The median GFR was lower, 28 mL/
min/1.73 m2, in the CRF group than the transplant group,
38 mL/min/1.73 m2 (P = 0.003, Mann-Whitney). Overall
mean serum calcium and ionized calcium concentrations
were within the normal range and did not differ between
patient groups (Table 3). Mean serum phosphate concen-
trations were 92% of the age-adjusted upper limit of nor-
mal range, which represents a value equivalent to about
the 75th centile of the age-dependent normal range. The
age-adjusted phosphate levels were significantly higher in
the dialyzed patients compared to both those with CRF
and transplanted patients (P < 0.002 post hoc Tamhane’s
T2). Over the course of the study the mean calcium phos-
phate product (Ca × P) was 42.4 mg2/dL2.
PTH concentrations and the 1-84 PTH:C-PTH ratio
Overall mean iPTH and CAP-PTH values were within
their normal ranges (Table 4). The haemodialysis patients
had mean iPTH and CAP-PTH concentrations just over
two times the upper limits of normal range and patients
on peritoneal dialysis had mean values that were about 1.5
times the upper limits of normal range (Table 4). Overall
correlation between mean PTH concentrations as mea-
sured by the two PTH assays was r = 0.975, P < 0.001.
In the CRF group there was a weak negative corre-
lation between GFR and iPTH (r = −0.24, P = 0.021)
but correlation with CAP-PTH was not significant (r =
−0.18, P = 0.08). In this CRF group there was also a weak
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Table 3. Biochemical summary data for patients throughout the study period
Chronic renal Hemodialysis Peritoneal Transplant
Measurement All Patients failure patients group dialysis group group P value
(normal range) (N = 162) (N = 96) (N = 7) (N = 19) (N = 40) (ANOVA)
Hemoglobin g/dL (10.0-14.5) 12.1 (8.5-18.2) 12.7 (10.1-18.2) 10.5 (8.5-12.8) 12 (9.3-15) 11.8 (9.6-15.4) <0.001
Sodium mmol/L (135-145) 140 (133-146) 140 (133-144) 139 (135-143) 139 (134-143) 141 (137-146) 0.022
Potassium mmol/L (3.5-5.5) 4.3 (3.0-6.1) 4.2 (3.0-5.4) 4.9 (3.6-6.1) 4.1 (3.4-5.1) 4.4 (3.3-5.3) <0.001
Bicarbonate mmol/L (18-26) 24 (18-31) 24 (18-29) 23 (20-26) 26 (21-31) 23 (19-27) <0.001
Calcium mmol/L (2.22-2.74) 2.37 (1.94-2.72) 2.37 (2.03-2.69) 2.35 (2.18-2.52) 2.37 (1.94-2.72) 2.35 (2.21-2.48) 0.77
Ionized calcium mmol/L (1.15-1.41) 1.25 (0.99-1.56) 1.26 (1.12-1.52) 1.21 (1.11-1.36) 1.25 (1.01-1.56) 1.25 (0.99-1.34) 0.371
Phosphatea Age-adjusted 0.92 (0.46-1.68) 0.89 (0.60-1.46) 1.03 (0.71-0.68) 1.11 (0.80-1.54) 0.87 (0.46-1.16) <0.001
magnesium mmol/L (0.74-1.0) 0.86 (0.59-1.91) 0.85 (0.60-1.31) 1.12 (0.89-1.37) 1.03 (0.63-1.91) 0.73 (0.59-0.92) <0.001
ALP U/L (110-440) 198 (48-1038) 201 (48-454) 337 (80-1038) 199 (69-415) 165 (56-298) <0.001
Albumin g/L (35-55) 39 (31-51) 40 (33-45) 38 (35-40) 36 (31-51) 41 (35-45) <0.001
Calcium phosphate product mg2/dL2 42.4 (19.6-79.3) 43.4 (25.3-79.3) 44.7 (31.8-68.6) 48.2 (35.4-64.2) 37.0 (19.6-47.4) <0.001
ANOVA is analysis of variance and compares all four patient groups. ALP is alkaline phosphatase. Range of overall summary data in parentheses.
aPhosphate expressed as proportion of age adjusted upper limit of normal.
Table 4. Mean parathyroid hormone (PTH) concentrations and 1-84 PTH:carboxy-terminal PTH (C-PTH) ratio by patient group
Chronic renal Hemodialysis Peritoneal Transplant
All patients failure patients group dialysis group group P value
(N = 162) (N = 96) (N = 7) (N = 19) (N = 40) ANOVA
iPTH pg/mL (14-66 pg/mL) 44.9 (5-596) 37.1 (5-514) 143.7 (42.3-541) 90.7 (10.0-596) 41.3 (15.3-195) <0.001
CAP-PTH pg/mL (5-39 pg/mL) 28.7 (1.7-403) 24.8 (1.7-368) 93.1 (21.2-387) 50.0 (3.0-403) 25.4 (7.0-87) <0.001
1-84 PTH:C-PTH ratio 2.5 (0.6-45) 3.0 (0.7-45) 2.6 (1.1-7.2) 1.6 (0.6-7.5) 2.0 (1.1-5.6) <0.001
Abbreviations are: iPTH, intact parthyroid hormone; CAP, cyclase-activating protein. Range of overall summary data in parentheses.
but significant correlation between the GFR and the 1-84
PTH:C-PTH ratio (r = 0.2, P = 0.047) (i.e., an increase
in C-PTH as CRF progresses). Increases in the relative
proportion of C-PTH were also found in dialyzed and
transplanted patients (Table 4) (P = 0.03 and P < 0.001,
respectively, post hoc Tamhane’s T2).
Overall, the ratio was significantly higher in those with
normal range CAP-PTH (2.7 compared to 2.1, P = 0.01)
compared to those with raised CAP-PTH concentrations
and in those with normal range iPTH compared to raised
iPTH (2.8 compared to 1.9, P = 0.001).
Change in height SDS
The height SDS and weight SDS at inclusion were sig-
nificantly lower than the normal population (P < 0.001
for both) (Table 5). The change in these anthropomet-
ric measures over the course of the study, expressed as
change in height SDS per year (HtSDS) and change
in weight SDS (WtSDS) were not different compared
with an expected mean change of zero in the normal pop-
ulation (P = 0.89 and P = 0.19, respectively). ANOVA
did not demonstrate any differences in HtSDS between
patient groups (P = 0.19), nor was there any difference
between the genders (P = 0.49). When split into three
equal groups, dependent upon length of time included in
the study, ANOVA did not demonstrate any difference
in the HtSDS (P = 0.19).
There was no relationship between either iPTH or
CAP-PTH concentrations and growth (r = −0.1, P = 0.22
and r = −0.06, P = 0.46, respectively).
In the CRF group there was a weak but significant
correlation between the HtSDS and the 1-84 PTH: C-
PTH ratio (r = 0.22, P = 0.03). The correlation between
HtSDS and the 1-84 PTH:C-PTH ratio persisted when
all patients were analyzed together (r = 0.2, P = 0.01) and
the relationship was emphasized by division of all the pa-
tients into three groups (tertiles) according to the 1-84
PTH:C-PTH ratio (ANOVA P = 0.039); the third of pa-
tients with the highest 1-84 PTH:C-PTH ratio grew better
than those with the lowest ratio (HtSDS = 0.086 (95%
CI −0.012 to +0.184) versus −0.086 (95% CI −0.165 to
−0.007) (P = 0.033).
Enteral feeds
Twenty-eight (17%) of the patients were fed entirely
or supplemented via gastrostomy feeding tubes. Seven-
teen were in the CRF group, 10 in the dialysis group, and
one patient was in the transplant group; patients in the
dialysis group were more likely to have a gastrostomy
(P = 0.002, chi-square).
As failure to thrive is an indication for employing this
modality of therapy, this group of artificially fed patients
were smaller; height SDS −1.75 compared to −1.20 (P =
0.028) and weight SDS −1.10 compared to −0.41 (P =
0.003). However, growth rates, HtSDS and WtSDS,
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Table 5. Height (Ht) and weight (wt) standard deviation score (SDS) and rate of change by patient group
P value t-test Chronic renal Hemodialysis Peritoneal Transplant
All patients combined failure group group dialysis group group P value
(N = 162) to (normal) (N = 96) (N = 7) (N = 19) (N = 40) ANOVA
HtSDS −1.27 P < 0.001 −1.26 −1.72 −1.48 −1.23 0.068
at inclusion (−4.75-2.27) (−4.75-2.27) (−3.18–0.52) (−3.7-0.71) (−3.64-0.61)
HtSDS 0.00 P = 0.89 0.04 0.08 −0.10 −0.08 0.19
(−1.16-1.06) (−1.16-0.89) (−0.32–0.84) (−0.42-0.50) (−0.58-1.06)
WtSDS −0.53 P < 0.001 −0.73 −0.58 −0.96 −0.16 0.004
at inclusion (−4.25-2.94) (−4.25-2.91) (−2.71–0.49) (−2.78-2.3) (−2.76-2.94)
WtSDS 0.08 P = 0.19 0.16 −0.37 0.17 −0.08 0.12
(−2.33-2.12) (−1.72-2.12) (−1.31–0.59) (−1.89-1.84) (−2.33-1.91)
Analysis of variance (ANOVA) dialysis patients combined.
were not significantly different compared to those fed
normally (P = 0.07 and P = 0.35, respectively).
Puberty
Pubertal assessment was undertaken in those over the
age of 9 years old. Ninety-two patients were older than
9 years and of these, 63 (68%) had pubertal assessments
(42 boys and 21 girls). No delayed entry into puberty
was found. The HtSDS was not different between those
who did and those who did not have pubertal assessments
(P = 0.8).
Prescription of calcium-based phosphate binders
and alfacalcidol
One hundred and eight (67%) of the patients were pre-
scribed calcium carbonate. The median (range) dose of
prescribed calcium carbonate was 90 mg/kg/day (16 to
692 mg/kg/day).
The prescription of calcium-based phosphate binder
was not associated with serum calcium concentrations,
age-adjusted serum phosphate concentrations, or PTH
concentrations (P = 0.054, P = 0.51 and P = 0.83, re-
spectively); nor was there a relationship with quantities
of binder prescribed and the HtSDS (r = −0.03, P =
0.77). There was, however, a positive correlation between
calcium carbonate prescription and the Ca × P product
(r = 0.37, P < 0.001).
The prescription of alfacalcidol was common (93%);
the median dose (range) was 12 ng/kg/day (1 to 95
ng/kg/day). There were no relationships between alfa-
calcidol prescription and serum calcium or age-adjusted
phosphate levels, but there was a weak positive correla-
tion with the Ca × P product (r = 0.18, P = 0.028). The
relationship with serum PTH concentrations was weak
(CAP-PTH, r = 0.2, P = 0.014; iPTH, r = 0.17, P = 0.04).
The quantity of alfacalcidol prescribed was not related
to the HtSDS (r = 0.0, P = 0.99).
Hypercalcemic episodes
During the study period there were five episodes of se-
vere hypercalcaemia (upper limit of reference range plus
∼10% equates to serum calcium >2.95 mmol/L) in five
patients prescribed alfacalcidol; three in the CRF group
and two on peritoneal dialysis. The frequency of these
episodes was equivalent to one episode of severe hyper-
calcaemia related to alfacalcidol every 36 patient years. In
four of the episodes, alfacalcidol was temporarily discon-
tinued but restarted at a lower dose once the hypercal-
caemia had resolved, in the fifth case it was not restarted;
serum calcium concentrations returned to normal within
a few weeks in all cases. One of the CRF patients suf-
fered a significant (>10%) increase in serum creatinine,
which returned to baseline following the fall in calcium
concentrations. One further episode of severe hypercal-
cemia was noted in a patient not prescribed alfacalcidol.
DISCUSSION
We have shown that our aim of maintaining nor-
mal calcium, phosphate, PTH concentrations and growth
rate was achievable using dietary phosphate restriction,
calcium-based phosphate binders, and small doses of al-
facalcidol in children with CRF. In patients on dialysis,
phosphate and PTH were less easy to control, but with
PTH concentrations up to twice the upper limit of the nor-
mal range growth was normal. There was no correlation
between PTH and growth rate, but a higher 1-84PTH:C-
PTH ratio was associated with better growth.
The lack of correlation between PTH concentrations
(iPTH or CAP-PTH) and growth is consistent with our
previous retrospective analysis of children with severe
CRF [15]. This is, however, in contrast to one previ-
ous study, in 24 prepubertal patients [14], which related
improved growth to increased iPTH concentrations, al-
though the authors state that the relationship demon-
strated was mainly dependent on the two patients with
the highest PTH. Perhaps this difference may be re-
lated to patient populations in that our sample includes
a large proportion of infants and young children fed with
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nasogastric or gastrostomy feeds. There are multiple in-
fluences upon growth especially in the face of uremia,
in particular nutrition, acidosis, and electrolyte imbal-
ances. These results should be interpreted within the
clinical context that strict attention was made to the opti-
mization of nutrition and correction of acidosis and elec-
trolyte imbalances, which undoubtedly underlies much of
the growth achieved. It is generally accepted that growth
should be measured over at least 12 months to avoid sea-
sonal changes [38]; however, while patients were included
for a median of 1.1 years the range was from 0.5 to 1.7
years. Nevertheless, there were no significant differences
in the growth rate dependent upon the length of inclusion
in the study (i.e., those followed for less than a year grew
no differently from those followed for longer).
The concentration of PTH that allows optimum growth
is a very important clinical issue, and will depend on both
whether the assay selected measures only 1-84 PTH or
1-84 and C-PTH, as well as the severity of CRF. This is
because, as we have also shown on cross-sectional data
[25], the proportion of C-PTH was higher when PTH
concentrations were outside the normal range, which be-
comes increasingly common as CRF progresses. Further-
more, as in adults, C-PTH concentrations rose as renal
function deteriorated [24] so that C-PTH was highest
in patients on dialysis [19, 39]. Our results did not re-
flect the strength of the relationship demonstrated in
these adult data, but this is perhaps because the ma-
jority of our patients maintained normal range PTH
concentrations.
One way of trying to adjust for the relative propor-
tion of active (1-84 PTH) and antagonistic fragments (C-
PTH) has been to use the 1-84 PTH:C-PTH ratio. In our
patients on dialysis (particularly peritoneal dialysis), the
1-84 PTH:C-PTH ratio was significantly reduced, reflect-
ing a disproportionate increase in C-PTH concentrations
compared to 1-84 PTH. This has been previously de-
scribed in small numbers of adult patients on peritoneal
dialysis [19]. It is likely that children and adults on dialysis
have the highest concentrations of both PTH and C-PTH,
due to the combination of hyperphosphatemic stimula-
tion of PTH secretion, decreased clearance of C-PTH
and nonphysiologic changes in serum calcium related to
dialysis that may adversely affect the relative proportions
of 1-84 PTH and C-PTH secreted.
Although we found no relationship between PTH con-
centrations and growth rate, there was a positive rela-
tionship between the HtSDS and the 1-84 PTH:C-PTH
ratio; the 95% CI for the HtSDS for the third of pa-
tients with the lowest ratio did not include zero, indicative
of suboptimal growth. This relationship does not imply
causality (i.e., it cannot be stated that a low ratio will slow
growth). Indeed, as concentrations of C-PTH increase
with worsening renal function and in dialyzed patients,
this relationship may simply be indicative of the effects
of worsening uremia on growth. However, given the func-
tional data that C-PTH antagonizes the biologic activity
of 1-84 PTH by acting at a receptor separate to the PTH
receptor [18, 20, 23], it remains a possibility that increased
levels of C-PTH may interfere with bone turnover and
consequently play a role in growth retardation. Although
normal PTH concentrations allow normal growth in chil-
dren with conservatively managed CRF, the optimum
PTH concentration for patients on dialysis is less clear;
dialysis patient numbers were smaller and fewer patients
had normal range PTH concentrations. Furthermore, as
we do not have bone histology, we are unable to com-
ment upon the affects of our therapeutic management
upon bone health and agree with previous suggestions
that more research is needed [40–43].
Another important aspect is to establish that no harm
is done by encouraging vascular calcification if a policy
of strict PTH control is followed; care should be taken
to avoid the excessive use of calcium-based phosphate
binders and the development of lower turnover renal os-
teodystrophy [44]. This is because high doses of calcium-
based phosphate binders have been associated with
vascular calcification [45] and it has recently been demon-
strated that therapeutic measures leading to over sup-
pression of the parathyroid gland (parathyroidectomy or
excessive calcium load) favor low bone turnover, which
may in turn influence arterial calcification [46]. In addi-
tion the positive relationship demonstrated between the
prescription of calcium-based binders and the Ca × P
product, even though relatively weak, is of concern as
an increased Ca × P product has been shown to be dis-
advantageous to long term cardiovascular morbidity and
mortality [47] and has been associated with soft tissue
calcification [48].
The use of vitamin D therapy is beneficial in altering
the natural course of renal osteodystrophy [49]. Indeed
the prescription of small doses of alfacalcidol in con-
junction with phosphate binders was highly efficacious
at controlling PTH concentrations. There appeared to
be no detrimental effects of the prescription of alfacal-
cidol upon growth, although it was occasionally associ-
ated with episodes of severe hypercalcemia. Large doses
of calcitriol have previously been associated with poor
growth in patients on dialysis [11], but conversely, the ini-
tial studies in children with CRF found improved growth
with low dose 1,25 (OH)2 vitamin D [50]. The infrequent
occurrence of severe hypercalcemic episodes, responsive
to drug withdrawal, did not appear to have any long-term
effects upon renal function, consistent with adult data
[49], but it is not known whether these severe hypercal-
cemic episodes will have had an adverse effect on vascu-
lar calcification. Again the positive relationship between
drug (alfacalcidol) prescription and Ca × P product is
of concern; it may reflect the calcemic effects and/or the
use of increased doses in those patients with the poorest
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serum PTH and phosphate control. Overall the mean Ca
× P product was only 42.2 mg2/dL2; the recommended
upper limit in adults is 55 mg2/dL2 [7, 47]. Thus while
calcium-based phosphate binders and alfacalcidol may
have potentially deleterious effects upon growth and car-
diovascular disease it should be noted that hyperparathy-
roidism is also a risk factor for cardiovascular morbidity
and mortality [5, 51, 52]. Alternatively, other noncalcium-
based phosphate binders may be more appropriate at
suppressing hyperparathyroidism without the calcium
burden [53].
CONCLUSION
Normal growth rate occurs in children with CRF man-
aged conservatively when the PTH (CAP-PTH or iPTH)
is within the normal range and with concentrations of up
to twice normal in children on dialysis. The role of C-PTH
in bone turnover and growth requires further investiga-
tion.
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